Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Prognostic Value of Macrophage Phenotypes in Resectable Non-Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry.

Rakaee M, Busund LR, Jamaly S, Paulsen EE, Richardsen E, Andersen S, Al-Saad S, Bremnes RM, Donnem T, Kilvaer TK.

Neoplasia. 2019 Mar;21(3):282-293. doi: 10.1016/j.neo.2019.01.005. Epub 2019 Feb 10.

2.

MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer.

Richardsen E, Andersen S, Melbø-Jørgensen C, Rakaee M, Ness N, Al-Saad S, Nordby Y, Pedersen MI, Dønnem T, Bremnes RM, Busund LT.

Sci Rep. 2019 Jan 23;9(1):386. doi: 10.1038/s41598-018-36854-7.

3.

A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer.

Grønberg BH, Sjøblom B, Wentzel-Larsen T, Baracos VE, Hjermstad MJ, Aass N, Bremnes RM, Fløtten Ø, Bye A, Jordhøy M.

Eur J Clin Nutr. 2018 Sep 25. doi: 10.1038/s41430-018-0325-5. [Epub ahead of print]

PMID:
30254241
4.

Progesterone Receptors in Prostate Cancer: Progesterone receptor B is the isoform associated with disease progression.

Grindstad T, Richardsen E, Andersen S, Skjefstad K, Rakaee Khanehkenari M, Donnem T, Ness N, Nordby Y, Bremnes RM, Al-Saad S, Busund LT.

Sci Rep. 2018 Jul 27;8(1):11358. doi: 10.1038/s41598-018-29520-5.

5.

Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer.

Rakaee M, Kilvaer TK, Dalen SM, Richardsen E, Paulsen EE, Hald SM, Al-Saad S, Andersen S, Donnem T, Bremnes RM, Busund LT.

Hum Pathol. 2018 Sep;79:188-198. doi: 10.1016/j.humpath.2018.05.017. Epub 2018 Jun 6.

PMID:
29885403
6.

Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors.

Hjelle LV, Gundersen POM, Hellesnes R, Sprauten M, Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Oldenburg J, Bremnes RM, Haugnes HS.

Acta Oncol. 2018 Oct;57(10):1392-1400. doi: 10.1080/0284186X.2018.1473641. Epub 2018 May 18.

PMID:
29775128
7.

Transcription factor PAX6 as a novel prognostic factor and putative tumour suppressor in non-small cell lung cancer.

Kiselev Y, Andersen S, Johannessen C, Fjukstad B, Standahl Olsen K, Stenvold H, Al-Saad S, Donnem T, Richardsen E, Bremnes RM, Rasmussen Busund LT.

Sci Rep. 2018 Mar 22;8(1):5059. doi: 10.1038/s41598-018-23417-z.

8.

Tissue analyses reveal a potential immune-adjuvant function of FAP-1 positive fibroblasts in non-small cell lung cancer.

Kilvaer TK, Rakaee M, Hellevik T, Østman A, Strell C, Bremnes RM, Busund LT, Dønnem T, Martinez-Zubiaurre I.

PLoS One. 2018 Feb 7;13(2):e0192157. doi: 10.1371/journal.pone.0192157. eCollection 2018.

9.

LAG-3 in Non-Small-cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated With Improved Survival.

Hald SM, Rakaee M, Martinez I, Richardsen E, Al-Saad S, Paulsen EE, Blix ES, Kilvaer T, Andersen S, Busund LT, Bremnes RM, Donnem T.

Clin Lung Cancer. 2018 May;19(3):249-259.e2. doi: 10.1016/j.cllc.2017.12.001. Epub 2017 Dec 11.

PMID:
29396238
10.

Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement.

Valan CD, Slagsvold JE, Halvorsen TO, Herje M, Bremnes RM, Brunsvig PF, Brustugun OT, Fløtten Ø, Levin N, Sundstrøm SH, Grønberg BH.

Anticancer Res. 2018 Feb;38(2):871-876.

PMID:
29374714
11.

Corrigendum to "Prognostic relevance of estrogen receptor α, β and aromatase expression in non-small cell lung cancer" [Steroids 113 (2016) 5-13].

Skjefstad K, Grindstad T, Rakaee Khanehkenari M, Richardsen E, Donnem T, Kilvaer T, Andersen S, Bremnes RM, Busund LT, Al-Saad S.

Steroids. 2018 Feb;130:36-37. doi: 10.1016/j.steroids.2017.11.010. Epub 2017 Dec 19. No abstract available.

PMID:
29273210
12.

High miR-205 expression in normal epithelium is associated with biochemical failure - an argument for epithelial crosstalk in prostate cancer?

Nordby Y, Richardsen E, Ness N, Donnem T, Patel HRH, Busund LT, Bremnes RM, Andersen S.

Sci Rep. 2017 Nov 24;7(1):16308. doi: 10.1038/s41598-017-16556-2.

13.

The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer.

Al-Saad S, Richardsen E, Kilvaer TK, Donnem T, Andersen S, Khanehkenari M, Bremnes RM, Busund LT.

PLoS One. 2017 Jul 25;12(7):e0181527. doi: 10.1371/journal.pone.0181527. eCollection 2017.

14.

CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases.

Paulsen EE, Kilvaer TK, Rakaee M, Richardsen E, Hald SM, Andersen S, Busund LT, Bremnes RM, Donnem T.

Cancer Immunol Immunother. 2017 Nov;66(11):1449-1461. doi: 10.1007/s00262-017-2039-2. Epub 2017 Jul 13.

15.

Muscle mass and association to quality of life in non-small cell lung cancer patients.

Bye A, Sjøblom B, Wentzel-Larsen T, Grønberg BH, Baracos VE, Hjermstad MJ, Aass N, Bremnes RM, Fløtten Ø, Jordhøy M.

J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):759-767. doi: 10.1002/jcsm.12206. Epub 2017 May 10.

16.

The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.

Ness N, Andersen S, Khanehkenari MR, Nordbakken CV, Valkov A, Paulsen EE, Nordby Y, Bremnes RM, Donnem T, Busund LT, Richardsen E.

Oncotarget. 2017 Apr 18;8(16):26789-26801. doi: 10.18632/oncotarget.15817.

17.

High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence.

Nordby Y, Richardsen E, Rakaee M, Ness N, Donnem T, Patel HR, Busund LT, Bremnes RM, Andersen S.

Sci Rep. 2017 Feb 24;7:43378. doi: 10.1038/srep43378.

18.

Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer.

Halvorsen TO, Herje M, Levin N, Bremnes RM, Brustugun OT, Fløtten Ø, Kaasa S, Sundstrøm S, Grønberg BH.

Lung Cancer. 2016 Dec;102:9-14. doi: 10.1016/j.lungcan.2016.10.003. Epub 2016 Oct 15.

PMID:
27987595
19.

Erratum to: Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival.

Hald SM, Kiselev Y, Al-Saad S, Richardsen E, Johannessen C, Eilertsen M, Kilvaer TK, Al-Shibli K, Andersen S, Busund LT, Bremnes RM, Donnem T.

BMC Cancer. 2016 Nov 24;16(1):916. No abstract available.

20.

Fibroblast miR-210 overexpression is independently associated with clinical failure in Prostate Cancer - a multicenter (in situ hybridization) study.

Andersen S, Richardsen E, Moi L, Donnem T, Nordby Y, Ness N, Holman ME, Bremnes RM, Busund LT.

Sci Rep. 2016 Nov 8;6:36573. doi: 10.1038/srep36573.

21.

Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.

Paulsen EE, Kilvaer TK, Khanehkenari MR, Al-Saad S, Hald SM, Andersen S, Richardsen E, Ness N, Busund LT, Bremnes RM, Donnem T.

Clin Lung Cancer. 2017 Mar;18(2):220-233.e8. doi: 10.1016/j.cllc.2016.09.009. Epub 2016 Oct 5.

22.

Prognostic effect of intratumoral neutrophils across histological subtypes of non-small cell lung cancer.

Rakaee M, Busund LT, Paulsen EE, Richardsen E, Al-Saad S, Andersen S, Donnem T, Bremnes RM, Kilvaer TK.

Oncotarget. 2016 Nov 1;7(44):72184-72196. doi: 10.18632/oncotarget.12360.

23.

Estrogen receptors α and β and aromatase as independent predictors for prostate cancer outcome.

Grindstad T, Skjefstad K, Andersen S, Ness N, Nordby Y, Al-Saad S, Fismen S, Donnem T, Khanehkenari MR, Busund LT, Bremnes RM, Richardsen E.

Sci Rep. 2016 Sep 9;6:33114. doi: 10.1038/srep33114.

24.

Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer.

Halvorsen TO, Sundstrøm S, Fløtten Ø, Brustugun OT, Brunsvig P, Aasebø U, Bremnes RM, Kaasa S, Grønberg BH.

Acta Oncol. 2016 Nov;55(11):1349-1354. Epub 2016 Aug 23.

PMID:
27549509
25.

Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.

Hjelle LV, Bremnes RM, Gundersen POM, Sprauten M, Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Oldenburg J, Haugnes HS.

Urol Oncol. 2016 Nov;34(11):487.e13-487.e20. doi: 10.1016/j.urolonc.2016.06.012. Epub 2016 Aug 11.

PMID:
27523611
26.

Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.

Usó M, Jantus-Lewintre E, Bremnes RM, Calabuig S, Blasco A, Pastor E, Borreda I, Molina-Pinelo S, Paz-Ares L, Guijarro R, Martorell M, Forteza J, Camps C, Sirera R.

Oncotarget. 2016 Aug 16;7(33):52849-52861. doi: 10.18632/oncotarget.10811.

27.

Prognostic relevance of estrogen receptor α, β and aromatase expression in non-small cell lung cancer.

Skjefstad K, Grindstad T, Khanehkenari MR, Richardsen E, Donnem T, Kilvaer T, Andersen S, Bremnes RM, Busund LT, Al-Saad S.

Steroids. 2016 Sep;113:5-13. doi: 10.1016/j.steroids.2016.05.008. Epub 2016 May 24. Erratum in: Steroids. 2017 Dec 19;:.

PMID:
27234503
28.

The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival.

Kilvaer TK, Paulsen EE, Khanehkenari MR, Al-Saad S, Johansen RM, Al-Shibli K, Bremnes RM, Busund LT, Donnem T.

Br J Cancer. 2016 May 10;114(10):1145-51. doi: 10.1038/bjc.2016.92. Epub 2016 Apr 7.

29.

Importance of tumor infiltrating lymphocytes in non-small cell lung cancer?

Bremnes RM, Donnem T, Busund LT.

Ann Transl Med. 2016 Apr;4(7):142. doi: 10.21037/atm.2016.03.28. No abstract available.

30.

Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer.

Sjøblom B, Grønberg BH, Wentzel-Larsen T, Baracos VE, Hjermstad MJ, Aass N, Bremnes RM, Fløtten Ø, Bye A, Jordhøy M.

Clin Nutr. 2016 Dec;35(6):1386-1393. doi: 10.1016/j.clnu.2016.03.010. Epub 2016 Apr 1.

PMID:
27102408
31.

The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer.

Bremnes RM, Busund LT, Kilvær TL, Andersen S, Richardsen E, Paulsen EE, Hald S, Khanehkenari MR, Cooper WA, Kao SC, Dønnem T.

J Thorac Oncol. 2016 Jun;11(6):789-800. doi: 10.1016/j.jtho.2016.01.015. Epub 2016 Feb 1. Review.

32.

Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer.

Donnem T, Kilvaer TK, Andersen S, Richardsen E, Paulsen EE, Hald SM, Al-Saad S, Brustugun OT, Helland A, Lund-Iversen M, Solberg S, Gronberg BH, Wahl SG, Helgeland L, Fløtten O, Pohl M, Al-Shibli K, Sandanger TM, Pezzella F, Busund LT, Bremnes RM.

Ann Oncol. 2016 Feb;27(2):225-32. doi: 10.1093/annonc/mdv560. Epub 2015 Nov 16. Review.

PMID:
26578726
33.

Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.

Grønberg BH, Halvorsen TO, Fløtten Ø, Brustugun OT, Brunsvig PF, Aasebø U, Bremnes RM, Tollåli T, Hornslien K, Aksnessæther BY, Liaaen ED, Sundstrøm S; Norwegian Lung Cancer Study Group.

Acta Oncol. 2016 May;55(5):591-7. doi: 10.3109/0284186X.2015.1092584. Epub 2015 Oct 23.

PMID:
26494411
34.

Lymphangiogenic Markers and Their Impact on Nodal Metastasis and Survival in Non-Small Cell Lung Cancer--A Structured Review with Meta-Analysis.

Kilvaer TK, Paulsen EE, Hald SM, Wilsgaard T, Bremnes RM, Busund LT, Donnem T.

PLoS One. 2015 Aug 25;10(8):e0132481. doi: 10.1371/journal.pone.0132481. eCollection 2015. Review.

35.

The prognostic significance of CXCL16 and its receptor C-X-C chemokine receptor 6 in prostate cancer.

Richardsen E, Ness N, Melbø-Jørgensen C, Johannesen C, Grindstad T, Nordbakken C, Al-Saad S, Andersen S, Dønnem T, Nordby Y, Bremnes RM, Busund LT.

Am J Pathol. 2015 Oct;185(10):2722-30. doi: 10.1016/j.ajpath.2015.06.013. Epub 2015 Aug 10.

PMID:
26272362
36.

Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy.

Nordby Y, Andersen S, Richardsen E, Ness N, Al-Saad S, Melbø-Jørgensen C, Patel HR, Dønnem T, Busund LT, Bremnes RM.

Prostate. 2015 Nov;75(15):1682-93. doi: 10.1002/pros.23048. Epub 2015 Aug 13.

PMID:
26268996
37.

Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.

Kilvaer TK, Khanehkenari MR, Hellevik T, Al-Saad S, Paulsen EE, Bremnes RM, Busund LT, Donnem T, Martinez IZ.

PLoS One. 2015 Aug 7;10(8):e0134965. doi: 10.1371/journal.pone.0134965. eCollection 2015.

38.

Organized metabolic crime in prostate cancer: The coexpression of MCT1 in tumor and MCT4 in stroma is an independent prognosticator for biochemical failure.

Andersen S, Solstad Ø, Moi L, Donnem T, Eilertsen M, Nordby Y, Ness N, Richardsen E, Busund LT, Bremnes RM.

Urol Oncol. 2015 Aug;33(8):338.e9-17. doi: 10.1016/j.urolonc.2015.05.013. Epub 2015 Jun 8.

PMID:
26066969
39.

Keratin 34betaE12/keratin7 expression is a prognostic factor of cancer-specific and overall survival in patients with early stage non-small cell lung cancer.

Pøhl M, Olsen KE, Holst R, Donnem T, Busund LT, Bremnes RM, Al-Saad S, Andersen S, Richardsen E, Ditzel HJ, Hansen O.

Acta Oncol. 2016;55(2):167-77. doi: 10.3109/0284186X.2015.1049291. Epub 2015 Jun 9.

PMID:
26057535
40.

Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival.

Hald SM, Kiselev Y, Al-Saad S, Richardsen E, Johannessen C, Eilertsen M, Kilvaer TK, Al-Shibli K, Andersen S, Busund LT, Bremnes RM, Donnem T.

BMC Cancer. 2015 May 29;15:441. doi: 10.1186/s12885-015-1446-z. Erratum in: BMC Cancer. 2016 Nov 24;16(1):916.

41.

Long-term platinum retention after platinum-based chemotherapy in testicular cancer survivors: a 20-year follow-up study.

Hjelle LV, Gundersen PO, Oldenburg J, Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Bremnes RM, Haugnes HS.

Anticancer Res. 2015 Mar;35(3):1619-25.

PMID:
25750319
42.

High progesterone receptor expression in prostate cancer is associated with clinical failure.

Grindstad T, Andersen S, Al-Saad S, Donnem T, Kiselev Y, Nordahl Melbø-Jørgensen C, Skjefstad K, Busund LT, Bremnes RM, Richardsen E.

PLoS One. 2015 Feb 27;10(2):e0116691. doi: 10.1371/journal.pone.0116691. eCollection 2015.

43.

Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer.

Donnem T, Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, Brustugun OT, Helland A, Lund-Iversen M, Poehl M, Olsen KE, Ditzel HJ, Hansen O, Al-Shibli K, Kiselev Y, Sandanger TM, Andersen S, Pezzella F, Bremnes RM, Busund LT.

Clin Cancer Res. 2015 Jun 1;21(11):2635-43. doi: 10.1158/1078-0432.CCR-14-1905. Epub 2015 Feb 13.

44.

The prognostic role of progesterone receptor expression in non-small cell lung cancer patients: Gender-related impacts and correlation with disease-specific survival.

Skjefstad K, Richardsen E, Donnem T, Andersen S, Kiselev Y, Grindstad T, Hald SM, Al-Shibli K, Bremnes RM, Busund LT, Al-Saad S.

Steroids. 2015 Jun;98:29-36. doi: 10.1016/j.steroids.2015.01.020. Epub 2015 Feb 7.

PMID:
25668612
45.

Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors.

Haugnes HS, Oldenburg J, Bremnes RM.

Urol Oncol. 2015 Sep;33(9):399-406. doi: 10.1016/j.urolonc.2014.11.012. Epub 2014 Dec 29. Review.

PMID:
25554583
46.

How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial.

Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo N, Aasebø U.

Clin Lung Cancer. 2015 May;16(3):183-92. doi: 10.1016/j.cllc.2014.08.005. Epub 2014 Nov 13.

47.

miRNA detection methods and clinical implications in lung cancer.

Usó M, Jantus-Lewintre E, Sirera R, Bremnes RM, Camps C.

Future Oncol. 2014 Nov;10(14):2279-92. doi: 10.2217/fon.14.93. Review.

48.

Stromal expression of MiR-21 predicts biochemical failure in prostate cancer patients with Gleason score 6.

Melbø-Jørgensen C, Ness N, Andersen S, Valkov A, Dønnem T, Al-Saad S, Kiselev Y, Berg T, Nordby Y, Bremnes RM, Busund LT, Richardsen E.

PLoS One. 2014 Nov 17;9(11):e113039. doi: 10.1371/journal.pone.0113039. eCollection 2014.

49.

Monocarboxylate transporters 1-4 in NSCLC: MCT1 is an independent prognostic marker for survival.

Eilertsen M, Andersen S, Al-Saad S, Kiselev Y, Donnem T, Stenvold H, Pettersen I, Al-Shibli K, Richardsen E, Busund LT, Bremnes RM.

PLoS One. 2014 Sep 16;9(9):e105038. doi: 10.1371/journal.pone.0105038. eCollection 2014.

50.

Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer.

Ness N, Andersen S, Valkov A, Nordby Y, Donnem T, Al-Saad S, Busund LT, Bremnes RM, Richardsen E.

Prostate. 2014 Oct;74(14):1452-61. doi: 10.1002/pros.22862. Epub 2014 Aug 11.

PMID:
25111810

Supplemental Content

Loading ...
Support Center